Pyruvic acid oxalacetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: Pyruvic acid oxalacetic acid
• 英文别名: 2-oxobutanedioic acid;2-oxopropanoic acid
• 化学式: C7H8O8
• 分子量: 220.13
• InChiKey: CTBYOENFSJTSBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.23
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Pyridopyrimidinones derivatives as telomerase inhibitors
  申请人：Pharmacia Italia S.p.A.

  公开号：US20040009993A1

  公开（公告）日：2004-01-15

  The invention provides novel pyrido[2,3-d]pyrimidin-7(8H)-ones derivatives active as telomerase inhibitors, the use of the derivatives as therapeutic agents, such as antitumoral agents, processes for preparation of the derivatives, and to pharmaceutical compositions comprising the derivatives.

  这项发明提供了作为端粒酶抑制剂活性的新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物，以及这些衍生物作为治疗剂（如抗肿瘤剂）的用途，制备这些衍生物的方法，以及包含这些衍生物的药物组合物。
• [EN] ANILINO LIVER X-RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RECEPTEURS X DU FOIE A STRUCTURE ANILINO
  申请人：PHARMACIA CORP

  公开号：WO2003099769A1

  公开（公告）日：2003-12-04

  The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.

  本发明涉及选择性LXR调节剂，对应于式I的小分子化合物，并进一步涉及利用式I化合物的治疗有效剂量来治疗受LXR调节的哺乳动物病症的方法。
• Antiangiogenic combination therapy for the treatment of cancer
  申请人：——

  公开号：US20020103141A1

  公开（公告）日：2002-08-01

  The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.

  本发明提供了一种DNA拓扑异构酶I抑制剂和选择性COX-2抑制剂的组合物，用于预防、治疗和/或减少哺乳动物发生肿瘤性疾病的风险。
• Farnesoid X-activated receptor agonists
  申请人：——

  公开号：US20040014734A1

  公开（公告）日：2004-01-22

  The invention relates to compounds of formula (I) 1 in which n, R 3 , R 4 , R 5 , R 6 , R 10 , R 13 , R 17 , X, Y, and Z are defined above. The invention also relates to pharmaceutical compositions each containing an effective amount of one or more compounds of formula (I) and a pharmaceutically acceptable carrier.

  该发明涉及式(I)中化合物，其中n、R3、R4、R5、R6、R10、R13、R17、X、Y和Z如上所定义。该发明还涉及含有式(I)中一种或多种化合物的有效量和一种药用可接受载体的药物组合物。
• Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
  申请人：Masferrer L. Jaime

  公开号：US20050187172A1

  公开（公告）日：2005-08-25

  The present invention provides combinations of a Cox-2 inhibitor and a DNA topoisomerase inhibitor and methods of use thereof for preventing and/or treating neoplasia or or a neoplasia-related disorder in a subject.

  本发明提供了一种COX-2抑制剂和DNA拓扑异构酶抑制剂的组合物，以及它们的使用方法，用于预防和/或治疗受试者中的肿瘤或与肿瘤相关的疾病。